NeuroSense Therapeutics (NRSN) Balance Sheet: Assets & Liabilities

NeuroSense Therapeutics (NRSN) Balance Sheet

As of Mar 31, 2026 (end of fiscal 2025), NeuroSense Therapeutics reported total assets of $1.03M and total liabilities of $2.59M. Shareholders' equity was negative at −$1.56M, meaning liabilities exceed assets. Total debt stood at $170.00K against $166.00K in cash and short-term investments, a net debt position of $4.00K.

NeuroSense Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for NeuroSense Therapeutics Ltd. (NRSN) - Annual data in millions USD
Breakdown	FY 2025	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Mar 2026	Dec 2025	Mar 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	0.17	0.17	3.38	3.38	2.64	2.64	3.54	11.06	0.70	0.90
Short-Term Investments	0.00	-	0.00	-	0.00	-	3.55	0.00	0.00	0.00
Cash & Short-Term Investments	0.17	0.17	3.38	3.38	2.64	2.64	7.09	11.06	0.70	0.90
Accounts Receivable	0.03	0.03	0.16	0.16	0.17	0.17	0.13	0.18	0.03	0.02
Inventory	0.00	0.45	0.00	0.74	0.00	-	0.00	-0.18	0.00	0.00
Other Current Assets	0.58	0.05	0.86	0.04	0.11	0.04	0.04	0.35	0.00	0.00
Total Current Assets	0.78	0.78	4.40	4.40	2.92	2.92	7.38	11.41	0.73	0.91
Non-Current Assets
Property, Plant & Equipment (Net)	0.23	0.23	0.15	0.15	0.25	0.25	0.31	0.02	0.01	0.01
Long-Term Investments	0.00	-	0.00	-	0.00	-	0.00	0.00	0.04	0.04
Other Non-Current Assets	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.00	0.00	0.00
Total Non-Current Assets	0.25	0.25	0.17	0.17	0.27	0.27	0.33	0.02	0.05	0.04
Total Assets	1.03	1.03	4.58	4.58	3.19	3.19	7.72	11.43	0.78	0.96
Current Liabilities
Accounts Payable	0.80	0.80	1.16	1.16	1.46	1.46	0.50	0.04	0.06	0.02
Short-Term Debt	0.10	-	0.07	-	0.07	-	0.06	0.00	0.00	0.00
Accrued Liabilities	-	1.62	-	0.76	-	1.93	1.23	0.56	0.07	-
Other Current Liabilities	1.62	1.72	0.76	0.83	1.93	2.00	1.16	0.56	0.07	0.01
Total Current Liabilities	2.52	2.52	1.99	1.99	3.46	3.46	1.73	0.60	0.12	0.04
Non-Current Liabilities
Long-Term Debt	0.07	0.07	0.00	-	0.07	0.07	0.15	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	-	0.00	-	1.41	1.41	0.22	1.83	0.00	0.00
Total Non-Current Liabilities	0.07	0.07	0.00	-	1.49	1.49	0.37	1.83	0.00	0.00
Total Liabilities	2.59	2.59	1.99	1.99	4.94	4.94	1.87	2.43	0.12	0.04
Stockholders' Equity
Common Stock	0.00	-	0.00	-	0.00	-	0.00	0.00	0.00	0.00
Retained Earnings	-47.79	-47.79	-36.66	-36.66	-26.12	-26.12	-20.79	-8.45	-4.41	-1.58
Accumulated Other Comprehensive Income	0.00	-	0.00	-	24.36	-	0.00	0.00	0.00	0.00
Additional Paid-in Capital	46.23	46.23	39.24	39.24	24.25	24.36	26.41	17.45	5.06	2.50
Shares Outstanding	-	1.63	-	1.16	-	0.77	0.59	10.94	-	-
Total Stockholders' Equity	-1.56	-1.56	2.58	2.58	-1.76	-1.76	5.84	9.01	0.66	0.92
Total Liabilities & Equity	1.03	1.03	4.58	4.58	3.18	3.19	7.71	11.43	0.78	0.96

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About NeuroSense Therapeutics Balance Sheet

How much debt does NeuroSense Therapeutics have?

NeuroSense Therapeutics had total debt of $170.00K as of Mar 31, 2026, against $166.00K in cash and short-term investments. Total debt was $73.00K a year earlier.

What are NeuroSense Therapeutics's total assets?

NeuroSense Therapeutics reported total assets of $1.03M as of Mar 31, 2026, down 77.5% from $4.58M a year earlier. Total liabilities were $2.59M.

What is NeuroSense Therapeutics's shareholders' equity?

NeuroSense Therapeutics's shareholders' equity was negative at −$1.56M as of Mar 31, 2026, so its liabilities exceeded its assets.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition